Anavex Life Sciences Corp (AVXL)

[georgejjl]

Catalysts to Drive Value during the remainder of calendar 2021

The company has multiple clinical milestones

> Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study – expected Q2 2021

> Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial – expected mid 2021

> Top-line data Phase 1 ANAVEX®3-71 clinical trial – expected mid 2021

> Top-line data EXCELLENCE: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected 2H 2021

> Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2021

> Pipeline expansion opportunities for ANAVEX®2-73

> Initiation of potentially pivotal Phase 2/3 Fragile X clinical trial – expected 2021

> Initiation of potentially pivotal Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2021

> Possible and probable FDA approval of NAVEX®2-73 (blarcamesine) for the treatment of Rett syndrome and/of PDD (Parkinson's disease dementia)

Good luck and GOD bless,